Skip to main content
SpringerLink
Log in

Clinical efficacy of bisphosphonate therapy for bone metastasis from breast cancer

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Bisphosphonates inhibit osteoclastic bone resorption and are being used as treatment for bone metastases from breast cancer. Intravenous bisphosphonate therapy can significantly reduce skeletal related events (SREs) when administered concurrently with chemotherapy or endocrine therapy. In addition, intravenous bisphosphonate monotherapy is also able to alleviate cancer induced bone pain, and to improve bone metastases in some patients. Oral bisphosphonates are not routinely used for the treatment of bone metastases due to their low bioavailability. However, minodronate, a bisphosphonate 100-fold more potent than pamidronate, is now in phase II clinical studies in Japan, and may alter the role of oral bisphosphonates in the treatment of bone metastasis from breast cancer. The ASCO guidelines recommend that patients with osteolytic bone metastases be treated not with bisphosphonate monotherapy, but with concurrent bisphosphonate and systemic therapy. In addition, it is also recommended that current standards of care for cancer pain, analgesics and radiotherapy, should not be replaced with bisphosphonate therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

SRE:

Skeletal related event

ASCO:

American Society of Clinical Oncology

ICTP:

Pyridinoline cross-linked carboxyterminal telopeptide type I collagen

Al:

Aromatase inhibitor

BMD:

Bone mineral density

ATAC:

Arimidex and Tamoxifen Alone or in Combination

References

  1. Mundy RM, Guise TA, Yoneda T: Biology of bone metastases. In: Harris JR, Lippman ME, Morrow M, Osborne CK eds, Diseases of the breast, 2nd ed, Lippincott Williams & Wilkins Co, Philadelphia, pp911–920, 2001.

    Google Scholar 

  2. Fleisch H: Bisphosphonates-Preclinical. In: Fleisch H eds, Bisphosphonates in bone disease, 4th ed, Academic Press, California, pp27–66, 2000.

    Google Scholar 

  3. Yoneda T, Sasaki A, Mundy GR: Osteolytic bone metastasis in breast cancer.Breast Cancer Res Treat 32: 73–84, 1994.

    Article  PubMed  CAS  Google Scholar 

  4. Mundy GR: Pharmacologic treatment for diseases of bone remodeling. In: Bone remodeling and its disorders, 2nd ed, Martin Dunitz, United Kingdom, pp83–106, 1999.

    Google Scholar 

  5. Ernst DS, MacDonald RN, Paterson AHG,et al: A double-blind crossover trial of intravenous clodronate in metastatic bone pain.J Pain Symptom Manage 7: 4–11, 1992.

    Article  PubMed  CAS  Google Scholar 

  6. Magnetto S, Boissier S, Delmas P,et al: Additive anti-tumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.Int J Cancer 83: 263–269, 1999.

    Article  PubMed  CAS  Google Scholar 

  7. Body JJ: Clinical research update.Cancer 80: 1699–1701, 1997.

    Article  PubMed  CAS  Google Scholar 

  8. Oura S, Tanino H, Yoshimasu T,et al: Bisphosphonate therapy for bone metastases from breast cancer: clinical results and a new therapeutic approach.Breast Cancer 7: 307–310, 2000.

    PubMed  CAS  Google Scholar 

  9. Oura S, Sakurai T, Yoshimura G,et al: Study on the safety of rapid infusion and the efficacy of incadronate against bone metastasis of breast cancer.Jpn J Cancer Chemother 26: 1623–1628, 1999 (In Japanese with English abstract).

    CAS  Google Scholar 

  10. Koizumi M, Kobayashi M, Furukawa M,et al: The bisphosphonate incadronate for bone metastases of breast cancer.Int J Clin Oncol 5: 241–246, 2000.

    Article  Google Scholar 

  11. Kohno N, Kitazawa S, Konishi M,et al: New treatment strategy for bone metastases from breast cancer.Breast Cancer 6: 292–297, 1999.

    Article  PubMed  Google Scholar 

  12. Lipton A: Bisphosphonates and breast carcinoma.Cancer 88: 3033–3037, 2000.

    Article  PubMed  CAS  Google Scholar 

  13. Radziwill AJ, Thurlimann B, Jungi WF: Improvement of palliation in pateints with osteolytic bone disease and unsatisfactory pain control after pretreatment with disodium pamidronate: an intra-patient dose escalation study.Onkologie 16: 174–177, 1993.

    Google Scholar 

  14. Thurlimann B, Morant R, Jungi WF: Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study.Support Care Cancer 2: 61–65, 1994.

    Article  PubMed  CAS  Google Scholar 

  15. Purohit OP, Anthony C, Radstone CR,et al: High-dose intravenous pamidronate for metastatic bone pain.Br J Cancer 70: 554–558, 1994.

    PubMed  CAS  Google Scholar 

  16. Lipton A, Theriault R, Hortobagyi GN,et al: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases.Cancer 88: 1082–1090, 2000.

    Article  PubMed  CAS  Google Scholar 

  17. van Breukelen FJM, Bijvoet OL, van Oosterom AT: Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-l, l-bisphosphonate (A.P.D).Lancet 1: 803–805, 1979.

    Article  PubMed  Google Scholar 

  18. van Vorten-Verzantvoort ATM, Cleton FJ, Hermans J,et al: Long-term bisphosphonate treatment of bone metastases in breast cancer patients - a follow-up study of effects on mortality and quality of life. In: Bijvoet OLM, Lipton A eds, Osteoclast inhibition in the management of malignancy-related bone disorders, Hogrefe & Huber, Lewiston N.Y., pp79–85, 1991.

    Google Scholar 

  19. Conte PF, Giannessi PG, Latreille J,et al: Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase I trial.Ann Oncol 5(Suppl 7): S41-S44, 1994.

    PubMed  Google Scholar 

  20. Conte PF, Latreille J, Mauriac L,et al: Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial.J Clin Oncol 14: 2552–2559, 1996.

    PubMed  CAS  Google Scholar 

  21. Glover D, Lipton A, Keller A,et al: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer.Cancer 74: 2949–2955, 1994.

    Article  PubMed  CAS  Google Scholar 

  22. Hortobagyi GN, Theriault RL, Porter L,et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases.N Engl J Med 335: 1785–1791, 1996.

    Article  PubMed  CAS  Google Scholar 

  23. Theriault RL, Lipton A, Hortobagyi GN,et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial.J Clin Oncol 17: 846–854, 1999.

    PubMed  CAS  Google Scholar 

  24. Hacking A, Gudgeon CA, McNaughton D,et al: Pamidronate (APD) as single infusion mkonotherapy in the treatment of bone metastases from breast cancer. In: Bijvoet OLM, Lipton A eds, Osteoclast inhibition in the management of malignancy-related bone disorders. Hogrefe & Huber Publishers, Lewiston N.Y., pp45–53, 1991,

    Google Scholar 

  25. Bachouchi M, Bruning PF, Soukop M,et al: Intravenous pamidronate (APD) in the treatment of osteolytic metastases of breast cancer- preliminary results of a multicentre study. In: Bijvoet OLM, Lipton A eds, Osteoclast inhibition in the management of malignancy-related bone disorders, Hogrefe & Huber, Lewiston N.Y., pp38–44, 1991.

    Google Scholar 

  26. Morton AR, Cantrill JA, Pillai GV,et al: Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.BMJ 297: 772–773, 1988.

    PubMed  CAS  Google Scholar 

  27. Coleman RE, Woll PJ, Scrivener W,et al: Treatment of bone metastases from breast cancer with (3-amino-l-hydroxypropylidene)-l,l-bisphosphonate (APD).Br J Cancer 58: 621–625, 1988.

    PubMed  CAS  Google Scholar 

  28. Tyrrell CJ, Tyrrell CJ: Role of pamidronate in the management of bone metastases from breast cancer: results of a noncomparative multicenter phase II trial.Ann Oncol 5(Suppl7): S37-S40, 1994.

    PubMed  Google Scholar 

  29. Lipton A, Glover D, Harvey H,et al: Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer.Ann Oncol 5(Suppl 7): S31-S35, 1994.

    PubMed  Google Scholar 

  30. Oura S, Sakurai T, Yoshimura G,et al: Pamidronate therapy for bone metastasis in breast cancer.Jpn J Breast Cancer 13: 351–356, 1998 (In Japanese with English abstract).

    Google Scholar 

  31. van Holten-Verzantvoort ATM, Hermans J, Beex LVAM,et al: Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?EurJ Cancer 32A: 450–454, 1996.

    Article  Google Scholar 

  32. van Holten-Verzantvoort ATM, Zweiderman AH, Aaronson NK,et al: The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer.Eur J Cancer 27: 544–549, 1991.

    Article  PubMed  Google Scholar 

  33. Paterson AHG, Powles TJ, Kanis JA,et al: Double-blind controlled trial of oral clodonate in patients with bone metastases from breast cancer.J Clin Oncol 11: 59–65, 1993.

    PubMed  CAS  Google Scholar 

  34. Major PP, Lipton A, Berenson J,et al: Oral bisphosphonates: A review of clinical use in patients with bone metastases.Cancer 88: 6–14, 2000.

    Article  PubMed  CAS  Google Scholar 

  35. Hillner BE, Ingle JN, Berenson JR,et al: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer.J Clin Oncol 18: 1378–1391, 2000.

    PubMed  CAS  Google Scholar 

  36. Oura S, Sakurai T, Yoshimura G,et al: Breast cancer with osteoblastic bone metastasis treated successfully with bisphosphonate: a case report.Jpn J Cancer Chemother 26: 1651–1655, 1999 (In Japanese with English abstract).

    CAS  Google Scholar 

  37. Oura S, Sakurai T, Yoshimura G,et al: Pamidronate therapy for chest pain derived from recurrence in the parasternal lymph node in a patient with breast cancer in the terminal stage.J Jpn Surg Assoc 58: 346–349, 1997 (In Japanese with English abstract).

    Google Scholar 

  38. Munster PN, Horton J: Tamoxifen vs aromatase inhibitors: News from San Antonio, 2001.Cancer Control 8: 478–479, 2001.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Surgery, Wakayama Medical University, Japan

    Shoji Oura, Issei Hirai, Tatsuya Yoshimasu, Yozo Kokawa, Rie Sasaki & Yoshitaka Okamura

Authors
  1. Shoji Oura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Issei Hirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tatsuya Yoshimasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yozo Kokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rie Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshitaka Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Reprint requests to Shoji Oura, First Department of Surgery, Wakayama Medical University, 811-1, Kimiidera, Wakayama-shi, Wakayama 641-0012, Japan.

About this article

Cite this article

Oura, S., Hirai, I., Yoshimasu, T. et al. Clinical efficacy of bisphosphonate therapy for bone metastasis from breast cancer. Breast Cancer 10, 28–32 (2003). https://doi.org/10.1007/BF02967622

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02967622

Key words

Search

Navigation